Integrating Patient-Reported Outcomes Into Prognostication in Gastroesophageal Cancer: Results of a Population-Based Retrospective Cohort Analysis
CONCLUSION: Patient's SB seems to carry a prognostic significance. ESAS and physician-reported ECOG exhibit comparable prognostic values. Physicians and patients can frequently have divergent opinions on PS. ESAS takes a patient-centered approach and should be encouraged in practice among patients with GEC as an additional tool for prognostication.PMID:38431782 | DOI:10.1093/oncolo/oyae010 (Source: The Oncologist)
Source: The Oncologist - March 3, 2024 Category: Cancer & Oncology Authors: Thais Baccili Cury Megid Divya Sharma Zeynep Baskurt Lucy Xiaolu Ma Xin Wang Carly C Barron Raymond Woo-Jun Jang Eric Xueyu Chen Carol Jane Swallow Aruz Mesci Jonathan Yeung Rebecca K S Wong Savtaj Singh Brar Patrick Veit-Haibach John Kim Yvonne Bach Hiro Source Type: research
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes
CONCLUSION: Our findings demonstrated improved outcomes with upfront 1L TT versus non-TT in patients with aNSCLC with ADOs and observed timely switching to TT after biomarker test result had similar outcomes to Upfront TT. Opportunities remain to improve the use of NGS for early ADO identification and determination of 1L TT.PMID:38417095 | DOI:10.1093/oncolo/oyae022 (Source: The Oncologist)
Source: The Oncologist - February 28, 2024 Category: Cancer & Oncology Authors: Thomas Stricker Neha Jain Esprit Ma Elaine Yu Rongrong Wang Robert Schuldt Richard Price Tania Szado Jesse Sussell Sarika Ogale Victor Lin Edward Arrowsmith Dennis Slater Daniel Vaena Harry Staszewski Bruno Fang Lasika Seneviratne Davey Daniel Source Type: research
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes
CONCLUSION: Our findings demonstrated improved outcomes with upfront 1L TT versus non-TT in patients with aNSCLC with ADOs and observed timely switching to TT after biomarker test result had similar outcomes to Upfront TT. Opportunities remain to improve the use of NGS for early ADO identification and determination of 1L TT.PMID:38417095 | DOI:10.1093/oncolo/oyae022 (Source: The Oncologist)
Source: The Oncologist - February 28, 2024 Category: Cancer & Oncology Authors: Thomas Stricker Neha Jain Esprit Ma Elaine Yu Rongrong Wang Robert Schuldt Richard Price Tania Szado Jesse Sussell Sarika Ogale Victor Lin Edward Arrowsmith Dennis Slater Daniel Vaena Harry Staszewski Bruno Fang Lasika Seneviratne Davey Daniel Source Type: research
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes
CONCLUSION: Our findings demonstrated improved outcomes with upfront 1L TT versus non-TT in patients with aNSCLC with ADOs and observed timely switching to TT after biomarker test result had similar outcomes to Upfront TT. Opportunities remain to improve the use of NGS for early ADO identification and determination of 1L TT.PMID:38417095 | DOI:10.1093/oncolo/oyae022 (Source: The Oncologist)
Source: The Oncologist - February 28, 2024 Category: Cancer & Oncology Authors: Thomas Stricker Neha Jain Esprit Ma Elaine Yu Rongrong Wang Robert Schuldt Richard Price Tania Szado Jesse Sussell Sarika Ogale Victor Lin Edward Arrowsmith Dennis Slater Daniel Vaena Harry Staszewski Bruno Fang Lasika Seneviratne Davey Daniel Source Type: research
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes
CONCLUSION: Our findings demonstrated improved outcomes with upfront 1L TT versus non-TT in patients with aNSCLC with ADOs and observed timely switching to TT after biomarker test result had similar outcomes to Upfront TT. Opportunities remain to improve the use of NGS for early ADO identification and determination of 1L TT.PMID:38417095 | DOI:10.1093/oncolo/oyae022 (Source: The Oncologist)
Source: The Oncologist - February 28, 2024 Category: Cancer & Oncology Authors: Thomas Stricker Neha Jain Esprit Ma Elaine Yu Rongrong Wang Robert Schuldt Richard Price Tania Szado Jesse Sussell Sarika Ogale Victor Lin Edward Arrowsmith Dennis Slater Daniel Vaena Harry Staszewski Bruno Fang Lasika Seneviratne Davey Daniel Source Type: research
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC
CONCLUSION: A well-designed DNA CGP assay is capable of robust fusion detection and these fusion calls are reliable for informing clinical decision-making. While DNA CGP detects most driver fusions, the clinical impact of fusion detection is substantial for individual patients and exhaustive efforts, inclusive of additional RNA-based testing, should be considered when an oncogenic driver is not clearly identified.PMID:38401173 | DOI:10.1093/oncolo/oyae028 (Source: The Oncologist)
Source: The Oncologist - February 24, 2024 Category: Cancer & Oncology Authors: Philip C Mack Rachel B Keller-Evans Gerald Li Katherine T Lofgren Alexa B Schrock Sally E Trabucco Justin M Allen Khaled Tolba Geoffrey R Oxnard Richard S P Huang Source Type: research
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC
CONCLUSION: A well-designed DNA CGP assay is capable of robust fusion detection and these fusion calls are reliable for informing clinical decision-making. While DNA CGP detects most driver fusions, the clinical impact of fusion detection is substantial for individual patients and exhaustive efforts, inclusive of additional RNA-based testing, should be considered when an oncogenic driver is not clearly identified.PMID:38401173 | DOI:10.1093/oncolo/oyae028 (Source: The Oncologist)
Source: The Oncologist - February 24, 2024 Category: Cancer & Oncology Authors: Philip C Mack Rachel B Keller-Evans Gerald Li Katherine T Lofgren Alexa B Schrock Sally E Trabucco Justin M Allen Khaled Tolba Geoffrey R Oxnard Richard S P Huang Source Type: research
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC
CONCLUSION: A well-designed DNA CGP assay is capable of robust fusion detection and these fusion calls are reliable for informing clinical decision-making. While DNA CGP detects most driver fusions, the clinical impact of fusion detection is substantial for individual patients and exhaustive efforts, inclusive of additional RNA-based testing, should be considered when an oncogenic driver is not clearly identified.PMID:38401173 | DOI:10.1093/oncolo/oyae028 (Source: The Oncologist)
Source: The Oncologist - February 24, 2024 Category: Cancer & Oncology Authors: Philip C Mack Rachel B Keller-Evans Gerald Li Katherine T Lofgren Alexa B Schrock Sally E Trabucco Justin M Allen Khaled Tolba Geoffrey R Oxnard Richard S P Huang Source Type: research
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC
CONCLUSION: A well-designed DNA CGP assay is capable of robust fusion detection and these fusion calls are reliable for informing clinical decision-making. While DNA CGP detects most driver fusions, the clinical impact of fusion detection is substantial for individual patients and exhaustive efforts, inclusive of additional RNA-based testing, should be considered when an oncogenic driver is not clearly identified.PMID:38401173 | DOI:10.1093/oncolo/oyae028 (Source: The Oncologist)
Source: The Oncologist - February 24, 2024 Category: Cancer & Oncology Authors: Philip C Mack Rachel B Keller-Evans Gerald Li Katherine T Lofgren Alexa B Schrock Sally E Trabucco Justin M Allen Khaled Tolba Geoffrey R Oxnard Richard S P Huang Source Type: research
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS
CONCLUSION: Extended treatment with darolutamide was well tolerated and no new safety signals were observed. Most ARi-associated and androgen-suppressive treatment-related TEAEs occurred at low incidences with darolutamide, were similar to placebo, and showed minimal increase over time with continued treatment.TRIAL NUMBER: ClinicalTrials.gov identifier NCT02200614.PMID:38394384 | DOI:10.1093/oncolo/oyae019 (Source: The Oncologist)
Source: The Oncologist - February 23, 2024 Category: Cancer & Oncology Authors: Neal D Shore Christian Gratzke Susan Feyerabend Patrick Werbrouck Joan Carles Egils Vjaters Teuvo L J Tammela David Morris Jeanny B Aragon-Ching Raoul S Concepcion Urban Emmenegger Neil Fleshner Markus Grabbert Vilnis Lietuvietis Hakim Mahammedi Felipe M Source Type: research
Adherence to Treatment and Follow-Up of Precancerous Cervical Lesions in Ethiopia
CONCLUSION: Our results revealed that adherence to treatment after VIA positive screening is relatively high whereas adherence to follow up recommendations still needs improvement. Reminders like appointment cards and phone calls can effectively reduce the loss of follow-up.PMID:38394385 | DOI:10.1093/oncolo/oyae027 (Source: The Oncologist)
Source: The Oncologist - February 23, 2024 Category: Cancer & Oncology Authors: Clara Yolanda Stroetmann Muluken Gizaw Rahel Alemayehu Abigiya Wondimagegnehu Friedemann Rabe Pablo Santos Bariki Mchome Blandina Theophil Mmbaga Adamu Addissie Eva Johanna Kantelhardt Source Type: research
A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX
Oncologist. 2024 Feb 23:oyad315. doi: 10.1093/oncolo/oyad315. Online ahead of print.ABSTRACTHomologous recombination repair (HRR) pathway deficiency opens multiple therapeutic avenues within pancreatic cancer. Patients with HRR deficiency-associated gene mutations such as BRCA1, BRCA2, and PALB2 are more susceptible to platinum-based chemotherapies and in those with somatic BRCA mutations, PARP inhibitor therapy prolongs progression-free survival. The case discussed herein illustrates the therapeutic opportunities offered through the identification of HRR deficiency in pancreatic cancer, as well as the challenges associate...
Source: The Oncologist - February 23, 2024 Category: Cancer & Oncology Authors: Jacob K Jamison Michael S May Alexander G Raufi Lyndon Luk Winston Wong Prabhjot S Mundi Gulam A Manji Source Type: research
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS
CONCLUSION: Extended treatment with darolutamide was well tolerated and no new safety signals were observed. Most ARi-associated and androgen-suppressive treatment-related TEAEs occurred at low incidences with darolutamide, were similar to placebo, and showed minimal increase over time with continued treatment.TRIAL NUMBER: ClinicalTrials.gov identifier NCT02200614.PMID:38394384 | DOI:10.1093/oncolo/oyae019 (Source: The Oncologist)
Source: The Oncologist - February 23, 2024 Category: Cancer & Oncology Authors: Neal D Shore Christian Gratzke Susan Feyerabend Patrick Werbrouck Joan Carles Egils Vjaters Teuvo L J Tammela David Morris Jeanny B Aragon-Ching Raoul S Concepcion Urban Emmenegger Neil Fleshner Markus Grabbert Vilnis Lietuvietis Hakim Mahammedi Felipe M Source Type: research
Adherence to Treatment and Follow-Up of Precancerous Cervical Lesions in Ethiopia
CONCLUSION: Our results revealed that adherence to treatment after VIA positive screening is relatively high whereas adherence to follow up recommendations still needs improvement. Reminders like appointment cards and phone calls can effectively reduce the loss of follow-up.PMID:38394385 | DOI:10.1093/oncolo/oyae027 (Source: The Oncologist)
Source: The Oncologist - February 23, 2024 Category: Cancer & Oncology Authors: Clara Yolanda Stroetmann Muluken Gizaw Rahel Alemayehu Abigiya Wondimagegnehu Friedemann Rabe Pablo Santos Bariki Mchome Blandina Theophil Mmbaga Adamu Addissie Eva Johanna Kantelhardt Source Type: research
A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX
Oncologist. 2024 Feb 23:oyad315. doi: 10.1093/oncolo/oyad315. Online ahead of print.ABSTRACTHomologous recombination repair (HRR) pathway deficiency opens multiple therapeutic avenues within pancreatic cancer. Patients with HRR deficiency-associated gene mutations such as BRCA1, BRCA2, and PALB2 are more susceptible to platinum-based chemotherapies and in those with somatic BRCA mutations, PARP inhibitor therapy prolongs progression-free survival. The case discussed herein illustrates the therapeutic opportunities offered through the identification of HRR deficiency in pancreatic cancer, as well as the challenges associate...
Source: The Oncologist - February 23, 2024 Category: Cancer & Oncology Authors: Jacob K Jamison Michael S May Alexander G Raufi Lyndon Luk Winston Wong Prabhjot S Mundi Gulam A Manji Source Type: research
